loading
前日終値:
$0.8701
開ける:
$0.87
24時間の取引高:
404.27K
Relative Volume:
0.52
時価総額:
$66.20M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-1.0365
EPS:
-0.84
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-12.52%
1か月 パフォーマンス:
-24.59%
6か月 パフォーマンス:
-53.22%
1年 パフォーマンス:
-32.97%
1日の値動き範囲:
Value
$0.835
$0.8817
1週間の範囲:
Value
$0.833
$1.0131
52週間の値動き範囲:
Value
$0.833
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
名前
Cytomx Therapeutics Inc
Name
セクター
Healthcare (1195)
Name
電話
650.515.3185
Name
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
職員
122
Name
Twitter
@cytomxinc
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
CTMX's Discussions on Twitter

CTMX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CTMX 0.8748 66.20M 101.21M -569.00K -56.88M -0.84
VRTX 450.42 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.72 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 590.27 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.44 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.08 24.89B 3.30B -501.07M 1.03B 11.54

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-05-28 アップグレード Piper Sandler Neutral → Overweight
2024-05-09 アップグレード Wedbush Neutral → Outperform
2024-05-06 アップグレード Jefferies Hold → Buy
2024-04-22 アップグレード JP Morgan Underweight → Neutral
2022-11-14 ダウングレード BMO Capital Markets Outperform → Market Perform
2022-07-07 ダウングレード Jefferies Buy → Hold
2022-07-07 ダウングレード Mizuho Buy → Neutral
2022-07-07 ダウングレード Piper Sandler Overweight → Neutral
2022-07-07 ダウングレード Wedbush Outperform → Neutral
2022-06-24 開始されました BMO Capital Markets Outperform
2022-01-18 アップグレード Barclays Underweight → Overweight
2021-11-15 開始されました BTIG Research Buy
2021-05-28 ダウングレード Barclays Equal Weight → Underweight
2021-03-29 開始されました JP Morgan Overweight
2021-03-23 アップグレード Jefferies Hold → Buy
2020-09-22 ダウングレード Guggenheim Buy → Neutral
2020-06-01 ダウングレード Jefferies Buy → Hold
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-03-24 アップグレード Wedbush Neutral → Outperform
2020-03-04 開始されました Barclays Equal Weight
2019-11-20 開始されました Guggenheim Buy
2019-11-11 ダウングレード Wedbush Outperform → Neutral
2019-06-13 開始されました Mizuho Buy
2019-05-14 開始されました Cantor Fitzgerald Overweight
2019-03-11 開始されました Barclays Overweight
2018-11-26 開始されました Piper Jaffray Overweight
2018-10-15 開始されました Goldman Neutral
2018-09-13 開始されました H.C. Wainwright Buy
2018-06-01 開始されました SunTrust Buy
2018-01-05 開始されました Citigroup Buy
2017-09-08 開始されました Wedbush Outperform
2017-03-27 開始されました H.C. Wainwright Buy
2017-03-02 開始されました Instinet Buy
2017-01-03 ダウングレード Oppenheimer Outperform → Perform
2015-11-02 開始されました Oppenheimer Outperform
すべてを表示

Cytomx Therapeutics Inc (CTMX) 最新ニュース

pulisher
Nov 19, 2024

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com

Nov 06, 2024
pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily

Oct 11, 2024
pulisher
Oct 06, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 06, 2024
pulisher
Sep 30, 2024

There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 29, 2024

Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech

Sep 25, 2024
pulisher
Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Reports Narrowed Losses - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 22, 2024

XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World

Sep 21, 2024

Cytomx Therapeutics Inc (CTMX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):